Millions of patients living with chronic skin conditions could see new treatment options on the horizon, as biopharmaceutical company Dermira, Inc. has secured $149.5M in funding. The capital infusion will fuel Dermira's commitment to bringing biotech ingenuity to medical dermatology, developing differentiated therapies by understanding the needs of both patients and physicians.
The company aims to transform how skin conditions are treated, serving as a bridge between unmet patient needs and significant scientific advances in understanding skin biology.
